Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

“…Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis (1744). The co-seasonal administration of omalizumab after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass-pollen allergic children (1745)(1746)(1747). This combination might prove useful for the treatment of allergic rhinitis, particularly for polysensitized patients.…”

Asthma-related comorbidities

“…Meta-analyses show that this treatment could be beneficial in pollen-induced rhinitis and asthma, but state that more investigations are needed to determine its efficacy in house dust mite allergy [70]. Recent studies found that adding anti-IgE therapy to SIT was significantly better at reducing symptoms of both seasonal allergic rhinitis [71] and asthma when compared with SIT alone [72], in addition to providing greater safety in adults as well as in children [73]. However, many guidelines consider SIT as a marginal treatment for asthma, although it is suggested for the types of allergic rhinitis mentioned earlier.…”

Pediatric Allergic Rhinitis and Asthma: Can the March be Halted?

“…Among these, omalizumab, a humanized monoclonal antibody that binds circulating IgE and prevents its attachment to high-affinity IgE receptors, is the most extensively studied agent approved for the treatment of severe uncontrolled asthma with perennial sensitizations. However, a growing number of reports indicate its effectiveness in seasonal and perennial AR in adults/adolescents [90][91][92][93][94] and children [95][96][97][98][99]. Targeting the early phase of the allergic cascade could prove a significant allergic march-preventing treatment.…”